The DOCK1 Knockout HeLa Polyclonal Cells product comprises a heterogeneous population of human cervical carcinoma HeLa cells edited by CRISPR/Cas9 to disrupt the DOCK1 gene locus. This polyclonal knockout model provides a loss-of-function platform for investigating DOCK1-dependent signaling pathways without the selection biases associated with single-cell-derived clones. The cell population is suitable for both transient and stable knockdown complementation studies and serves as a flexible tool for dissecting DOCK1 biology in a well-characterized epithelial cancer background.
HeLa cells, originally derived from a cervical adenocarcinoma, are HPV18-positive and exhibit adherent epithelial morphology. This immortalized line is a cornerstone of biomedical research, widely employed as a model for cervical carcinoma and cancer biology studies. The robust growth characteristics and extensive molecular characterization of HeLa cells facilitate reproducible experimental setups, making them an ideal host for gene-editing approaches. DOCK1 knockout in this context allows researchers to directly assess the contribution of DOCK1 to processes such as proliferation, migration, and invasion in a clinically relevant tumor cell type.
DOCK1 (dedicator of cytokinesis 1) functions as a guanine nucleotide exchange factor (GEF) that specifically activates the small GTPase Rac1 by promoting the exchange of GDP for GTP. Upon activation, DOCK1, often in a complex with ELMO scaffolding proteins, transduces signals from upstream receptors??including integrins, receptor tyrosine kinases (e.g., EGFR, PDGFR), and G protein-coupled receptors??to downstream effectors controlling cytoskeletal reorganization. Active Rac1 stimulates PAK kinases, the WAVE regulatory complex, and the Arp2/3 complex, culminating in actin polymerization and lamellipodia formation. This signaling axis governs cell motility, adhesion dynamics, phagocytosis, and neurite outgrowth.
In the HeLa cervical carcinoma model, DOCK1-mediated Rac1 activation plays a pivotal role in driving the invasive and migratory phenotypes associated with cancer metastasis. Loss of DOCK1 expression is expected to impair lamellipodia protrusion and reduce cellular motility, thereby providing a system to dissect the molecular underpinnings of tumor cell dissemination. Moreover, HeLa cells engineered with DOCK1 knockout can be used to screen for compensatory pathways or to evaluate the dependency of oncogenic signaling on DOCK1-driven cytoskeletal remodeling, offering insights into potential therapeutic targets for limiting cancer spread.
Typical applications of these polyclonal knockout cells include in vitro wound-healing assays to measure collective cell migration, transwell migration and invasion assays to assess chemotactic potential, and quantitative actin staining to visualize cytoskeletal changes. Researchers can also employ Rac1 activation assays (e.g., G-LISA) to confirm downstream signaling ablation, co-immunoprecipitation to examine DOCK1-ELMO complex formation, and western blotting to validate DOCK1 protein loss. For additional technical specifications and ordering information, please contact Ascent Research.
